Becaplermin

DB00102

biotech approved investigational

Deskripsi

Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

very little systemic absorption. 15% of patients experienced complete healing within 8 weeks, while for 25% of patients, it was at 10 weeks.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Target Protein

Platelet-derived growth factor receptor beta PDGFRB
Platelet-derived growth factor receptor alpha PDGFRA
Alpha-2-macroglobulin A2M

Referensi & Sumber

Link

Contoh Produk & Brand

Produk: 5 • International brands: 0
Produk
  • Regranex
    Gel • 100 ug/1g • Topical • US • Approved
  • Regranex
    Gel • 100 ug/1g • Topical • US • Approved
  • Regranex
    Gel • 100 ug/1g • Topical • US • Approved
  • Regranex
    Gel • 0.01 % • Cutaneous • EU
  • Regranex (becaplermin) 0.01%
    Gel • 100 mcg / g • Topical • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul